Total Payments
$11,658
2024 Payments
$27.31
Companies
7
Transactions
24
Medicare Patients
23,570
Medicare Billing
$15.1M
Payment Breakdown by Category
Other$11,424 (98.0%)
Food & Beverage$233.44 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Acquisitions | $6,652 | 1 | 57.1% |
| Current or prospective ownership or investment interest | $4,772 | 6 | 40.9% |
| Food and Beverage | $233.44 | 10 | 2.0% |
| Unspecified | $0 | 7 | 0.0% |
Payments by Type
General
$11,658
17 transactions
Ownership
$0
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US Retina LLC | $11,424 | 14 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $85.52 | 3 | $0 (2024) |
| Genentech USA, Inc. | $43.25 | 2 | $0 (2022) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $30.67 | 2 | $0 (2021) |
| Apellis Pharmaceuticals, Inc. | $30.56 | 1 | $0 (2023) |
| Coherus Biosciences Inc. | $22.24 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $21.20 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27.31 | 1 | Regeneron Healthcare Solutions, Inc. ($27.31) |
| 2023 | $6,742 | 5 | US Retina LLC ($6,652) |
| 2022 | $1,881 | 4 | US Retina LLC ($1,859) |
| 2021 | $1,611 | 5 | US Retina LLC ($1,577) |
| 2020 | $577.95 | 2 | US Retina LLC ($577.95) |
| 2019 | $797.82 | 4 | US Retina LLC ($757.94) |
| 2018 | $0 | 1 | US Retina LLC |
| 2017 | $20.90 | 2 | Genentech USA, Inc. ($20.90) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/16/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $27.31 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/20/2023 | Coherus Biosciences Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Ophthalmology | ||||||
| 07/21/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $36.78 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/13/2023 | US Retina LLC | — | Acquisitions | Cash or cash equivalent | $6,652.00 | General |
| 03/14/2023 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $30.56 | General |
| 2023 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 08/12/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/13/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $1,616.45 | General |
| 04/12/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $242.47 | General |
| 2022 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 11/05/2021 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/11/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $1,369.70 | General |
| 05/06/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $207.74 | General |
| 03/17/2021 | Bausch & Lomb, a division of Bausch Health US, LLC | VISUDYNE (Drug) | Food and Beverage | In-kind items and services | $11.99 | General |
| Category: Ophthalmology | ||||||
| 2021 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 03/13/2020 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $577.95 | General |
| 2020 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 11/19/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/25/2019 | Bausch & Lomb, a division of Bausch Health US, LLC | VISUDYNE (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: OPHTHALMOLOGY | ||||||
| 02/21/2019 | US Retina LLC | — | Current or prospective ownership or investment interest | Stock option | $757.94 | General |
| 2019 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 2018 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 01/20/2017 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: Ophthalmology | ||||||
| 2017 | US Retina LLC | — | — | — | $0.00 | Ownership |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 6,120 | 24,893 | $5.9M | $4.2M |
| 2022 | 16 | 6,485 | 17,174 | $5.7M | $4.3M |
| 2021 | 17 | 5,941 | 15,417 | $4.8M | $3.7M |
| 2020 | 17 | 5,024 | 12,430 | $3.8M | $2.9M |
Total Patients
23,570
Total Services
69,914
Medicare Billing
$15.1M
Procedure Codes
66
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 408 | 4,676 | $4.4M | $3.2M | 72.8% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 27 | 8,580 | $332,475 | $248,665 | 74.8% |
| 67028 | Injection of drug into eye | Office | 2023 | 464 | 2,318 | $431,195 | $230,130 | 53.4% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 1,227 | 1,582 | $212,433 | $140,897 | 66.3% |
| 92134 | Imaging of retina | Office | 2023 | 1,416 | 3,732 | $161,557 | $114,610 | 70.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 23 | 544 | $130,560 | $97,077 | 74.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 484 | 831 | $81,088 | $57,266 | 70.6% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 248 | 248 | $39,257 | $28,426 | 72.4% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 1,029 | 1,243 | $32,574 | $23,281 | 71.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 82 | 96 | $13,224 | $9,157 | 69.2% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 487 | 727 | $12,089 | $8,607 | 71.2% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 57 | 133 | $12,057 | $7,346 | 60.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $8,081 | $5,270 | 65.2% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 24 | 24 | $6,190 | $4,680 | 75.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 35 | 35 | $4,850 | $3,473 | 71.6% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 65 | 80 | $4,175 | $3,046 | 72.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 397 | 4,760 | $4.4M | $3.4M | 77.9% |
| 67028 | Injection of drug into eye | Office | 2022 | 466 | 2,369 | $439,555 | $238,206 | 54.2% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 26 | 757 | $256,445 | $164,452 | 64.1% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 1,237 | 1,639 | $220,775 | $146,836 | 66.5% |
| 92134 | Imaging of retina | Office | 2022 | 1,416 | 3,817 | $165,408 | $119,230 | 72.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 513 | 821 | $80,240 | $58,072 | 72.4% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 310 | 310 | $49,239 | $33,852 | 68.8% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 1,251 | 1,507 | $39,565 | $27,663 | 69.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 113 | 136 | $18,613 | $13,764 | 73.9% |
About Dr. Zac Ravage, MD
Dr. Zac Ravage, MD is a Ophthalmology healthcare provider based in Harvey, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992871248.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Zac Ravage, MD has received a total of $11,658 in payments from pharmaceutical and medical device companies, with $27.31 received in 2024. These payments were reported across 24 transactions from 7 companies. The most common payment nature is "Acquisitions" ($6,652).
As a Medicare-enrolled provider, Ravage has provided services to 23,570 Medicare beneficiaries, totaling 69,914 services with total Medicare billing of $15.1M. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Harvey, IL
- Active Since 11/28/2006
- Last Updated 02/04/2022
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1992871248
Products in Payments
- EYLEA (Biological) $85.52
- VISUDYNE (Drug) $30.67
- VABYSMO (Drug) $22.35
- Cimerli (Biological) $22.24
- BEOVU (Drug) $21.20
- Lucentis (Biological) $20.90
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Harvey
Mathew Maccumber, Md, MD
Ophthalmology — Payments: $248,259
Ophthalmology $248,259
Kourous Rezaei, Md, MD
Ophthalmology — Payments: $98,698
Ophthalmology $98,698
David Orth, Md, MD
Ophthalmology — Payments: $70,789
Ophthalmology $70,789
Timothy Flood, Md, MD
Ophthalmology — Payments: $57,253
Ophthalmology $57,253
Dr. Vivek Chaturvedi, M.d, M.D
Ophthalmology — Payments: $48,512
Ophthalmology $48,512
Serge Debustros, Md, MD
Ophthalmology — Payments: $34,365
Ophthalmology $34,365